Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maze Therapeutics (MAZE) Invested Capital (2024 - 2026)

Maze Therapeutics' Invested Capital history spans 3 years, with the latest figure at $380.5 million for Q1 2026.

  • On a quarterly basis, Invested Capital rose 30.29% to $380.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $380.5 million, a 30.29% increase, with the full-year FY2025 number at $355.0 million, up 214.07% from a year prior.
  • Invested Capital hit $380.5 million in Q1 2026 for Maze Therapeutics, up from $355.0 million in the prior quarter.
  • Over the last five years, Invested Capital for MAZE hit a ceiling of $380.5 million in Q1 2026 and a floor of -$403.7 million in Q1 2024.
  • Historically, Invested Capital has averaged $45.3 million across 3 years, with a median of $262.2 million in 2025.
  • Biggest five-year swings in Invested Capital: surged 233.35% in 2025 and later surged 30.29% in 2026.
  • Tracing MAZE's Invested Capital over 3 years: stood at -$311.2 million in 2024, then surged by 214.07% to $355.0 million in 2025, then grew by 7.2% to $380.5 million in 2026.
  • Business Quant data shows Invested Capital for MAZE at $380.5 million in Q1 2026, $355.0 million in Q4 2025, and $379.4 million in Q3 2025.